ALK-Abelló A/S Stock Value
ALK-Abelló A/S Company Info
EPS Growth 5Y
102,00%
Market Cap
kr45,60 B
Long-Term Debt
kr0,15 B
Quarterly earnings
05/06/2026 (E)
Dividend
kr1,61
Dividend Yield
0,78%
Founded
1923
Industry
Country
Website
ISIN Number
Website
Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.
kr255,00
23.91%
Last Update: 04/03/2026
Analysts: 2
Highest Price Target kr255,00
Average Price Target kr255,00
Lowest Price Target kr255,00
In the last five quarters, ALK-Abelló A/S’s Price Target has risen from kr129,10 to kr186,00 - a 44,07% increase. Three analysts predict that ALK-Abelló A/S’s share price will increase in the coming year, reaching kr255,00. This would represent an increase of 23,91%.
Top growth stocks in the health care sector (5Y.)
What does ALK-Abelló A/S do?
ALK-Abelló A/S operates as an allergy solutions company.
Products and Services
The company offers a diverse range of products and services centered on allergy treatment through immunotherapy. The primary product lines include allergen immunotherapy tablets and injections, which are tailored to address various types of allergies including pollen, house dust mites, and animal dander.
The sublingual immunotherapy tablets are particularly notable for their convenience and ease of use, providing r...
ALK-Abelló A/S Questions and Answers
Which sectors generate sales and which are the top 3 markets?
**Pharmaceutical Industry:** Main sector for ALK-Abelló A/S
**Top 3 Markets:**
1. **USA:** approx. 35%
2. **Germany:** approx. 20%
3. **France:** approx. 15%
ALK-Abelló A/S is a leading company in the pharmaceutical industry, specializing in allergy vaccines. The majority of revenues come from the...
At which locations are the company’s products manufactured?
**Production sites of ALK-Abelló A/S:**
1. **Denmark** - Headquarters and central production site
2. **France** - Production facilities
3. **Spain** - Production capacities
4. **USA** - Production and distribution sites
ALK-Abelló A/S is a globally active company specializing in the production of...
What strategy does ALK-Abelló A/S pursue for future growth?
**Revenue Growth:** Estimated at 10-12% annually (2025-2027)
**Focus on Innovation:** Increase in R&D spending by 15% (2024)
ALK-Abelló A/S pursues a growth strategy that is strongly focused on innovation and expansion into new markets. The company invests significantly in research and develo...
Which raw materials are imported and from which countries?
**Main raw materials:** Allergens, pharmaceutical active ingredients
**Countries of origin:** USA, Germany, France
ALK-Abelló A/S specializes in the production of allergy vaccines and requires specific allergens and pharmaceutical active ingredients for this purpose. These raw materials are mainl...
How strong is the company’s competitive advantage?
**Market share in allergy immunotherapy:** Approximately 30% (2024)
**Research and development investments:** 18% of revenue (2024)
**Patent portfolio:** Over 100 active patents (2024)
ALK-Abelló A/S is a leading company in the field of allergy immunotherapy and holds a significant market share...
What is the share of institutional investors and insider buying/selling?
**Institutional Investor Share:** approximately 40% (estimated, based on 2023 data)
**Insider Buys/Sells:** No significant transactions in the last year (estimated, based on 2023 data)
The institutional investor share in ALK-Abelló A/S is typically around 40%. This demonstrates institutional inves...
What percentage market share does ALK-Abelló A/S have?
**Market share of ALK-Abelló A/S:** 12% (2025, estimated)
**Main competitors and their market shares:**
1. **Stallergenes Greer:** 15%
2. **Thermo Fisher Scientific:** 14%
3. **ALK-Abelló A/S:** 12%
4. **Merck KGaA:** 10%
5. **HAL Allergy Group:** 8%
6. **Allergy Therapeutics:** 7%
7. **Aimmune The...
Is ALK-Abelló A/S stock currently a good investment?
**Revenue Growth:** 10% (2024)
**Research and Development Expenses:** 15% of revenue (2024)
**Market Share in the Allergy Segment:** 25% (2024)
ALK-Abelló A/S achieved a revenue growth of 10% in 2024, driven by strong demand for their allergy products. The company continues to invest significantly...
Does ALK-Abelló A/S pay a dividend – and how reliable is the payout?
**Dividend:** No payout (as of 2025)
ALK-Abelló A/S has not distributed any dividends to its shareholders in recent years. The company has focused on investing its resources in research and development as well as expanding its product lines.
This strategy is reflected in the decision to retain pro...
